Results of clinical trials with an allogeneic melanoma tumor cell lysate vaccine:: Melacine®

被引：88

作者：

Sondak, VK

Sosman, JA

机构：

[1] Univ Michigan, Div Surg Oncol, Hlth Syst, Ann Arbor, MI 48109 USA

[2] Vanderbilt Univ, Sch Med, Div Hematol Oncol, Nashville, TN 37027 USA

来源：

SEMINARS IN CANCER BIOLOGY | 2003年 / 13卷 / 06期

关键词：

melanoma; cancer vaccines; adjuvant therapy; immunotherapy; HLA antigens;

D O I：

10.1016/j.semcancer.2003.09.004

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The identification of proteins and carbohydrates associated with melanoma led to development of defined antigen vaccines. However, vaccines derived from whole allogeneic cells have a number of advantages. Melacine((R))( is an allogeneic melanoma tumor cell lysate combined with an immunologic adjuvant, DETOX(R). Phase I and II trials in stage IV melanoma showed low-level antitumor activity, but this vaccine has its greatest promise in the adjuvant setting. A phase III trial indicated a survival benefit for Melacine((R)) in the subset of melanoma patients who express the HLA class I antigens A2 and/or HLA-C3. This finding must now be prospectively confirmed. (C) 2003 Elsevier Ltd. All rights reserved.

引用

页码：409 / 415

页数：7

共 32 条

[1] Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma [J].

Balch, CM ;

Buzaid, AC ;

Soong, SJ ;

Atkins, MB ;

Cascinelli, N ;

Coit, DG ;

Fleming, ID ;

Gershenwald, JE ;

Houghton, A ;

Kirkwood, JM ;

McMasters, KM ;

Mihm, MF ;

Morton, DL ;

Reintgen, DS ;

Ross, MI ;

Sober, A ;

Thompson, JA ;

Thompson, JF .

JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (16) :3635-3648

[2] TREATMENT OF MURINE LEUKAEMIA WITH X-RAYS AND HOMOLOGOUS BONE MARROW .2. [J].

BARNES, DWH ;

LOUTIT, JF .

BRITISH JOURNAL OF HAEMATOLOGY, 1957, 3 (03) :241-252

[3]

COULIE PG, 1994, J EXP MED, V180, P435

[4]

ELLIOTT GT, 1993, SEMIN SURG ONCOL, V2, P41

[5] HUMAN GENE MAGE-3 CODES FOR AN ANTIGEN RECOGNIZED ON A MELANOMA BY AUTOLOGOUS CYTOLYTIC T-LYMPHOCYTES [J].

GAUGLER, B ;

VANDENEYNDE, B ;

VANDERBRUGGEN, P ;

ROMERO, P ;

GAFORIO, JJ ;

DEPLAEN, E ;

LETHE, B ;

BRASSEUR, F ;

BOON, T .

JOURNAL OF EXPERIMENTAL MEDICINE, 1994, 179 (03) :921-930

[6] Is the survival of melanoma patients receiving polyvalent melanoma cell vaccine linked to the human leukocyte antigen phenotype of patients? [J].

Hoon, DSB ;

Okamoto, T ;

Wang, HJ ;

Elashoff, R ;

Nizze, AJ ;

Foshag, LJ ;

Gammon, G ;

Morton, DL .

JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (04) :1430-1437

[7] Influence of TNFα and LTα single nucleotide polymorphisms on susceptibility to and prognosis in cutaneous malignant melanoma in the British population [J].

Howell, WM ;

Turner, SJ ;

Collins, A ;

Bateman, AC ;

Theaker, JM .

EUROPEAN JOURNAL OF IMMUNOGENETICS, 2002, 29 (01) :17-23

[8] Identification of NY-ESO-1 epitopes presented by human histocompatibility antigen (HLA)-DRB4*0101-0103 and recognized by CD4+ T lymphocytes of patients with NY-ESO-1-expressing melanoma [J].

Jäger, E ;

Jäger, D ;

Karbach, J ;

Chen, YT ;

Ritter, G ;

Nagata, Y ;

Gnjatic, S ;

Stockert, E ;

Arand, M ;

Old, LJ ;

Knuth, A .

JOURNAL OF EXPERIMENTAL MEDICINE, 2000, 191 (04) :625-630

[9]

Kamarashev J, 2001, INT J CANCER, V95, P23, DOI 10.1002/1097-0215(20010120)95:1<23::AID-IJC1004>3.0.CO

[10]

2-4

← 1 2 3 4 →